KD Pharma Group and Herbolea Biotech Sign Licensing Agreement for Use of Bio-Herbolysis™ Extraction Technology
KD Pharma Group | June 24, 2020
The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe. Bio-Herbolysis™ is a highly scalable, solvent-less and environmentally friendly technology that can extract cannabis' full phytocomplex starting from wet or dry material, yielding 90%+ extraction efficiency while preserving its original acidic forms and terpene profile. KD Pharma has the largest isolation and fractionation technology portfolio in the lipids industry and with this agreement will expand its capacity for manufacturing a full spectrum of cannabis and terpene-based products for use in pharmaceutical, dietary supplement and medicinal food products.